SNCA and Parkinson disease: PD, which affects nearly 4 in 100 people over the course of a lifetime [26], characterized by progressive loss of dopaminergic neurons of the substantia nigra pars compacta (SNpc) and concurrent aggregation of the synapse-associated protein α-synuclein (aSYN) [35], shares many pathophysiological features associated with LSDs.